Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Conference Call November 11, 2024 8:30 AM ET
Company Participants
Jenene Thomas – IR
Walter Klemp – Chairman and CEO
John Paul Waymack – Senior CMO
Jonathan Foster – EVP and CFO
Conference Call Participants
Jonathan Aschoff – Roth MKM
Jason McCarthy – Maxim Group
Vernon Bernardino – H.C. Wainwright
Operator
Greetings, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. At this time, all participants are in listen only mode. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It’s now my pleasure to introduce your host, Jenene Thomas, Investor Relations. Please go ahead, Jenene.
Jenene Thomas
Thank you, Kevin. Good morning and welcome, everyone. At this time I would like to remind our listeners that remarks made during this webcast may state management’s intentions, beliefs, expectations or future projections. These are forward looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the Company’s website and on the Securities and Exchange Commission’s website. We encourage you to review these documents carefully.
Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company’s own estimates and research. While the Company believes these
Read the full article here
